학술논문

miR-200a/b/-429 downregulation is a candidate biomarker of tumor radioresistance and independent of hypoxia in locally advanced cervical cancer.
Document Type
Academic Journal
Author
Nilsen A; Department of Radiation Biology, Norwegian Radium Hospital, Oslo University Hospital, Norway.; Hillestad T; Department of Core Facilities, Norwegian Radium Hospital, Oslo University Hospital, Norway.; Skingen VE; Department of Radiation Biology, Norwegian Radium Hospital, Oslo University Hospital, Norway.; Aarnes EK; Department of Radiation Biology, Norwegian Radium Hospital, Oslo University Hospital, Norway.; Fjeldbo CS; Department of Radiation Biology, Norwegian Radium Hospital, Oslo University Hospital, Norway.; Hompland T; Department of Radiation Biology, Norwegian Radium Hospital, Oslo University Hospital, Norway.; Department of Core Facilities, Norwegian Radium Hospital, Oslo University Hospital, Norway.; Evensen TS; Department of Core Facilities, Norwegian Radium Hospital, Oslo University Hospital, Norway.; Stokke T; Department of Core Facilities, Norwegian Radium Hospital, Oslo University Hospital, Norway.; Kristensen GB; Department of Gynecological Oncology, Norwegian Radium Hospital, Oslo University Hospital, Norway.; Institute of Cancer Genetics and Informatics, Oslo University Hospital, Norway.; Grallert B; Department of Radiation Biology, Norwegian Radium Hospital, Oslo University Hospital, Norway.; Lyng H; Department of Radiation Biology, Norwegian Radium Hospital, Oslo University Hospital, Norway.; Department of Physics, University of Oslo, Norway.
Source
Publisher: John Wiley & Sons, Inc Country of Publication: United States NLM ID: 101308230 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1878-0261 (Electronic) Linking ISSN: 15747891 NLM ISO Abbreviation: Mol Oncol Subsets: MEDLINE
Subject
Language
English
Abstract
Many patients with locally advanced cervical cancer experience recurrence within the radiation field after chemoradiotherapy. Biomarkers of tumor radioresistance are required to identify patients in need of intensified treatment. Here, the biomarker potential of miR-200 family members was investigated in this disease. Also, involvement of tumor hypoxia in the radioresistance mechanism was determined, using a previously defined 6-gene hypoxia classifier. miR-200 expression was measured in pretreatment tumor biopsies of an explorative cohort (n = 90) and validation cohort 1 (n = 110) by RNA sequencing. Publicly available miR-200 data of 79 patients were included for the validation of prognostic significance. A score based on expression of the miR-200a/b/-429 (miR-200a, miR-200b, and miR-429) cluster showed prognostic significance in all cohorts. The score was significant in multivariate analysis of central pelvic recurrence. No association with distant recurrence or hypoxia status was found. Potential miRNA target genes were identified from gene expression profiles and showed enrichment of genes in extracellular matrix organization and cell adhesion. miR-200a/b/-429 overexpression had a pronounced radiosensitizing effect in tumor xenografts, whereas the effect was minor in vitro. In conclusion, miR-200a/b/-429 downregulation is a candidate biomarker of central pelvic recurrence and seems to predict cell adhesion-mediated tumor radioresistance independent of clinical markers and hypoxia.
(© 2022 The Authors. Molecular Oncology published by John Wiley & Sons Ltd on behalf of Federation of European Biochemical Societies.)